Overview

A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Status:
Recruiting

Trial end date:
2024-10-29

Target enrollment:

Participant gender:

Summary

Study MO39874 is an open-label, phase IIIb, single arm, multicenter study conducted in participants with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not received chemotherapy for their unresectable locally advanced or metastatic disease.

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Atezolizumab
Paclitaxel